NCT06130384View on ClinicalTrials.gov

Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.

PHASE4CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

August 15, 2023

Study Completion Date

November 15, 2023

Conditions
PainIntravitreal InjectionPain, Acute
Interventions
DRUG

Use of bromfenac 0.09% to reduce intravitreal injection pain

The eyedrop (bromfenac) will be given to the assigned eye.

DRUG

Use of artificial tears to reduce intravitreal injection pain

The eyedrop (artificial tears) will be given to the assigned eye.

Trial Locations (5)

18017

Mid Atlantic Retina, Bethlehem

19107

Mid Atlantic Retina, Philadelphia

78240

Retina Consultants of San Antonio, San Antonio

02114

Ophthalmic Consultants of Boston, Boston

Unknown

University of Toronto, Toronto

All Listed Sponsors
lead

Wills Eye

OTHER

NCT06130384 - Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection. | Biotech Hunter | Biotech Hunter